Role of MicroRNA-30c in cancer progression

MicroRNAs (miRNAs or miRs) is a non-coding small RNA of a type of 18~24 nucleotide-regulated gene that has been discovered in recent years. It mainly degrades the target gene mRNA or inhibits its translation process through the complete or incomplete bindings with 3'UTR of target genes, followe...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Cancer 2020-01, Vol.11 (9), p.2593-2601
Main Authors: Han, Wenyan, Cui, Hongwei, Liang, Junqing, Su, Xiulan
Format: Article
Language:English
Subjects:
Apoptosis
Biosynthesis
Breast cancer
Cell growth
Chromosomes
Endometrial cancer
Estrogens
Gene expression
Genomes
Lung cancer
Metabolism
Metastasis
MicroRNAs
Prostate
Proteins
Review
RNA polymerase
Roles
Signal transduction
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:MicroRNAs (miRNAs or miRs) is a non-coding small RNA of a type of 18~24 nucleotide-regulated gene that has been discovered in recent years. It mainly degrades the target gene mRNA or inhibits its translation process through the complete or incomplete bindings with 3'UTR of target genes, followed by the regulation of individual development, apoptosis, proliferation, differentiation and other life activities through the post-transcriptional regulation. Among many miRNAs, the microRNA family, miR-30, plays diverse roles in these key process of neoplastic transformation, metastasis, and clinical outcomes in different cancer progression. As key member of miR-30, miR-30c is regulated by oncogenic transcription factors and cancer progression related genes. Recently, numerous studies have demonstrated that the aberrant expression of miR-30c was significantly associated with the majority of human cancer progression. In this review, the diverse roles of miR-30c in different cancer progression such as the cellular and molecular mechanisms, the potential applications in clinics were summarized to speculate the benefits of miR-30c over-expression in cancer treatment and prognosis.
ISSN:1837-9664
1837-9664
DOI:10.7150/jca.38449